← SynDRA
LORLATINIB
SynDRA canonical compound SYN0038017 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ALK | ROS1 |
|---|
| Mechanism of action | ALK tyrosine kinase receptor inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ALK
- ROS1
- FES
- EGFR
- EML4
- FER
- FRK
- JAK2
- LTK
- NTRK1
- NTRK2
- NTRK3
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- EML4 INHIBITOR
- ROS1 INHIBITOR
- PTK2 INHIBITOR
- NTRK1 INHIBITOR
- FER INHIBITOR
- TNK2 INHIBITOR
- NTRK2 INHIBITOR
- PTK2B INHIBITOR
- NTRK3 INHIBITOR
- LTK INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- ADORA3
- HTR1A
- NR1I2
- ACVR1
- SLC6A2
- MLNR
- SLC6A4
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- KDR
- MAOA
- MC3R
- SLC6A3
- SLC29A1
- NR3C1
- HRH3
- OPRM1
- PDE3A
- PDE4D
- PGR
- PPARG
- PTGS2
- SCN5A
- OPRD1
- HRH1
- HDAC6
- CCKAR
- ADORA1
- ADORA2A
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
- AGTR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CD74
- CP2C9
- CP3A7
- CYP3A4
- EML4
- SLC34A2
Drug classes
- Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2B6 Inducers
- Organic Anion Transporter 3 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Cytochrome P450 3A Inducers
- P-Glycoprotein Inducers
- Organic Cation Transporter 1 Inhibitors
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- LORBRENA
- Lorbrena
- lorbrena
- PF-06463922
- PF-6463922
- lorviqua
- Lorviqua
- SCHEMBL15274056
- Loratinib
- UNII-OSP71S83EU
- Lorlatinib,PF-06463922
- OSP71S83EU
- lorlantinib
- 4clj
- 4cli
- Lorlatinib [USAN:INN]
- Lorlatinib (JAN/USAN/INN)
- PF06463922(Lorlatinib)
- GTPL7476
- SCHEMBL15261807
- EX-A828
- MolPort-035-789-724
- KS-00000T6C
- 2641AH
- ZINC98208524
- s7536
- MFCD28144520
- BDBM50018830
- AKOS027250753
- DB12130
- CS-39
- PF 06463922
- PF06463922
- CHEMBL3286830
- C21H19FN6O2
- lorlatinibum
- Lorbrena (TN)
- LORLATINIB [MI]
Reported adverse events
- Arthralgia
- Constipation
- Fatigue
- Headache
- Hypertension
- Myalgia
- Nausea
- Pneumonitis
- Rash
- Back pain
- Bronchitis
- Chest pain
Look up LORLATINIB in the interactive SynDRA portal →